US-Firma Lattice Biologics Medikament gegen Corona
Seite 1 von 3 Neuester Beitrag: 27.04.20 17:37 | ||||
| Eröffnet am: | 16.03.20 11:48 | von: HolgerAktien | Anzahl Beiträge: | 55 |
| Neuester Beitrag: | 27.04.20 17:37 | von: Nano123 | Leser gesamt: | 11.831 |
| Forum: | Börse | Leser heute: | 9 | |
| Bewertet mit: |  | |||
| Seite: < | 2 | 3 > | ||||
https://finance.yahoo.com/news/...te-anti-inflammatory-110000983.html
AmnioBoost has potential for use in the treatment of ARDS, which is the principal cause of death in COVID-19 infection.1 Mortality in COVID-19 infected patients with the inflammatory lung condition (ARDS) is reported to approach 50%, and is associated with older age, co-morbidities such as diabetes, higher disease severity, and elevated markers of inflammation.1 Current therapeutic interventions do not appear to improve in-hospital survival.1
This is supported by recently published results from an investigator-initiated clinical study conducted in China which reported that allogeneic mesenchymal stem cells (MSCs) cured or significantly improved functional outcomes in all seven treated patients with severe COVID-19 pneumonia.
Die Aktie ist direkt am Freitag durch die Decke (knapp 200% mit Handelsvolumen von 25 Mio Aktien) gegangen. Bin mal gespannt, wie es heute bzw. die nächsten Wochen weitergeht. Handel findet überwiegend in Kanada und USA statt.
https://www.stockwatch.com/News/...877711&symbol=LBL®ion=C
Lattice to evaluate AmnioBoost for coronavirus patients
2020-03-13 07:15 ET - News Release
Mr. Guy Cook reports
LATTICE BIOLOGICS TO EVALUATE ANTI-INFLAMMATORY STEM CELL THERAPY TREATMENT OF COVID-19 LUNG DISEASE
Lattice Biologics Ltd. plans to evaluate its amniotic fluid concentrate, AmnioBoost, in patients with acute respiratory distress syndrome (ARDS) caused by coronavirus (COVID-19)
AmnioBoost has potential for use in the treatment of ARDS, which is the principal cause of death in Covid-19 infection (1). Mortality in Covid-19 infected patients with the inflammatory lung condition (ARDS) is reported to approach 50 per cent, and is associated with older age, co-morbidities such as diabetes, higher disease severity and elevated markers of inflammation (1). Current therapeutic interventions do not appear to improve in-hospital survival (1).
AmnioBoost is believed to have immunomodulatory properties to counteract the inflammatory processes that are implicated in several diseases by down regulating the production of pro-inflammatory cytokines, increasing production of anti-inflammatory cytokines and enabling recruitment of naturally occurring anti-inflammatory cells to involved tissues.
Major anti-inflammatory cytokines found in AmnioBoost include: interleukin (IL)-1beta, IL-1ra, TNF-alpha, IL-6, IL-8, IL-16, CCL2, CXCL7, MIF, and GRO a/b/g. Specific cytokine receptors for IL-1, and tumour necrosis factor-alpha, function as pro-inflammatory cytokine inhibitors.
This is supported by recently published results from an investigator-initiated clinical study conducted in China which reported that allogeneic mesenchymal stem cells (MSCs) cured or significantly improved functional outcomes in all seven treated patients with severe Covid-19 pneumonia (2).
AmnioBoost
AmnioBoost was originally developed for chronic adult inflammatory conditions such as osteoarthritis, but has found multiple uses in the treatment of bone and cartilage repair, as well as soft tissue repair. It is an investigational therapy comprising concentrated allogeneic MSCs and cytokines derived from amniotic fluid.
The amniotic fluid is donated from non-related, healthy mothers and recovered by caesarian section; the baby is not harmed in any way. Additionally, AmnioBoost has been injected in over 1,000 patients with no adverse events, and appears to be well tolerated.
References
(1) Y. Liu et al. Clinical features and progression of acute respiratory distress syndrome in coronavirus disease 2019. Medrxiv 2020.
(2) Z. Leng, et al. Transplantation of ACE2-Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia[J]. Aging and Disease.
About Lattice Biologics Ltd.
Lattice Biologics is an emerging leader in the field of cellular therapies and tissue engineering, with a focus on dental indications.
Lattice Biologics develops and manufactures biologic products to domestic and international markets. The company's products are used in a variety of surgical applications.
https://www.pharmaceutical-technology.com/news/...ovid-19-treatments/
Lattice Biologics is set to study its amniotic fluid concentrate, AmnioBoost, for the treatment of patients suffering from acute respiratory distress syndrome (ARDS) caused by Covid-19.
The company believes that AmnioBoost possesses the potential to treat ARDS.
AmnioBoost is thought to have immunomodulatory properties that can act against the inflammatory processes linked to several diseases.
It acts via down-regulation of the production of the pro-inflammatory cytokines, increasing anti-inflammatory cytokines production and facilitating recruitment of natural anti-inflammatory cells.
AmnioBoost consists of interleukin (IL)-1beta, IL-1ra, TNF-alpha, IL-6, IL-8, IL-16, CCL2, CXCL7, MIF and GRO a / b / g, among other anti-inflammatory cytokines.
The company’s new research is based on recent data from a clinical study in China, where allogeneic mesenchymal stem cells (MSCs) cured or significantly improved outcomes in seven patients with severe Covid-19 pneumonia.
Envoyer par e-mail
03/17/2020 | 01:00 pm
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces it has begun enrolling patients in its Phase 1 clinical trial to address safety and efficacy of its novel stem cell technology, AmnioBoost, for the treatment of severe acute respiratory syndrome (SARS) related to COVID-19 infection.
AmnioBoost is derived from amniotic fluid taken from non-related, healthy, living donors during a Caesarian delivery. The baby is not harmed in any way.
To be eligible for the U.S. trial, individuals must have laboratory confirmed infection with COVID-19 and evidence of lung involvement requiring supplemental oxygen or mechanical ventilation. The study will not enroll individuals with mild symptoms or individuals who are asymptomatic.
All potential patients will undergo a physical exam, participants will then be randomized into the investigational group or the placebo group. Individuals enrolled into the investigational group will receive ~ 5 million stem cells of AmnioBoost on the first day of enrollment and will receive another ~ 5 million stem cells on the second day of enrollment.
Clinicians will monitor the patients’ temperature, blood pressure, need for supplemental oxygen, and other factors daily to determine daily scores based on a scale of clinical outcomes.
In the initial stage of investigation, the clinicians will compare participant outcomes on day seven in both groups to assess if AmnioBoost treatment has produced any clinical benefit.
The study will be halted if there is no evidence of a treatment difference between AmnioBoost and placebo.
Initial patient enrollment in the trial will be limited to 10 patients and conducted in the Seattle area, as it is one of the most concentrated areas of COVID -19 infection in the United States.
“We thank the patients in advance for their participation in this cost free to the patient trial. We look forward to using a novel technology in the treatment of this highly infectious disease and to make sure the trial is carried out in the most effective manner possible,” said Guy Cook, CEO of Lattice Biologics Ltd.
In addition, the Company announces that it was named in a statement of claim filed January 2019 by Cheryl Farmer, the former Chief Financial Officer of the Company, for wrongful dismissal in the amount of $2.5 million USD. The Company and the plaintiff have come to a satisfactory resolution and Lattice Biologics trusts that Ms. Farmer will have success in her future endeavors.
The Company reserved $600,000 Canadian in its most recent audited financial statements. The settlement includes a severance payment of $100,000 to be paid over 9 months, and 18 million shares at $.05 Canadian. The shares are subject to TSX approval, and all regulatory restrictions.
Further, the Company has arranged a non-brokered private placement of up to 10 million units ("Units") at a price of $0.10 per Unit for aggregate gross proceeds of $1,000,000 (the "Offering"). Each Unit will be comprised of one common share ("Share") and one–half transferable Share purchase warrant of the Company ("Warrant"). Each full Warrant will entitle the Subscriber to purchase one Warrant Share for a 24 month period after the Closing Date at an exercise price of $0.10 per share. Proceeds raised from the Offering will be used for the expansion of its stem cell technology to address CONVID-19. Finders' fees may be payable on the private placement, subject to the policies of the TSX Venture Exchange.
This offering is subject to TSX Venture Exchange acceptance and expected to close March 30, 2020.
The Company also announces that its Board of Directors has today approved the grant of 3 million stock options to directors, and 6 million shares to employees and consultants, which are exercisable into common shares of LBL.V at a price of $0.075 per common share in accordance with TSX Policy 4.4, subject to the rules of the TSX Venture Exchange and the Corporation's Stock Option Plan. The options have a term of five years and will expire on March 16, 2025.
About Lattice Biologics Ltd.:
Lattice Biologics is traded on the TSX-V under the symbol: LBL. The Company is an emerging personalized/precision medicine leader in the field of cellular therapies and tissue engineering, with a focus on bone, skin, and cartilage regeneration.
Lattice Biologics develops and manufactures biologic products to domestic and international markets. The Company’s products are used in a variety of surgical applications.
Lattice Biologics maintains its headquarters, laboratory and manufacturing facilities in Belgrade, Montana as well as offices in Phoenix, Arizona. The facility includes ISO Class 1000 and ISO Class 100 clean rooms, and specialized equipment capable of crafting traditional allografts and precision specialty allografts for various clinical applications. The Lattice Biologics team includes highly trained tissue bank specialists, surgical technicians, certified sterile processing and distribution technicians, and CNC operators who maintain the highest standards of aseptic technique throughout each step of the manufacturing process. From donor acceptance to the final packaging and distribution of finished allografts, Lattice is committed to maintaining the highest standards of allograft quality, innovation, and customer satisfaction.
Hier nochmal die News von heute:
https://www.stockwatch.com/News/...878697&symbol=LBL®ion=C
Besser in Kanada die Aktien erwerben. Dort ist mehr Traffic.
Ich rechne mit weitere BIG News!